Haemodialysis: Uncovering new frontiers
 
Haemodialysis: Uncovering new frontiers

Recent technological advances in dialysis have not been translated into significant improvement in clinical outcomes. Patients on dialysis still exhibit uraemic symptoms, as well as systemic manifestations. Accumulation of larger uraemic toxins may contribute significantly to poor clinical outcomes in haemodialysis patients. Our distinguished faculty will provide delegates with a state-of-the-art update on the toxicity of uraemic solutes, with a focus on large middle molecules. Delegates will also be updated on emerging data linking uraemic inflammation to clinical events, as well as to uraemic solutes. Finally, delegates will be introduced to the concept of expanded haemodialysis (HDx), a new therapy option enabled by recent innovation in membrane design.

Programme

  • Introductions and welcome
  • Uncovering the unmet need:The scientific rationale
    Colin Hutchison, New Zealand
  • Innovation meeting the need
    Chris McIntyre, Canada
  • A new therapy: Rise of HDx
    Claudio Ronco, Italy
  • Summary and close
 
Webinar Registration
 
 
Webinar Details

Scientific Chair
Angelito Bernardo, USA

Faculty
Colin Hutchison, New Zealand
Chris McIntyre, Canada
Claudio Ronco, Italy

Wednesday 25 April 2018, 16:40–18:10 WEST

Baxter Kidney Collaborative Round Table
Rabat, Morocco

More Information
 
Privacy at Baxter | Copyright and Legal Disclaimers | Linking Disclaimers
© Copyright 2018 Baxter, All Rights Reserved
GLBL/MG3/18-0009